DE69942981D1 - Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie - Google Patents

Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Info

Publication number: DE69942981D1
Authority: DE; Germany
Prior art keywords: flt4; vegfr; imaging; target; antitumor therapy
Prior art date: 1998-10-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69942981T

Other languages

English (en)

Inventor

Kari Alitalo

Arja Kaipainen

Reija Valltola

Lotta Jussila

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vegenics Pty Ltd

Original Assignee

Vegenics Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-09

Filing date

1999-10-08

Publication date

2011-01-05

1998-10-09 Priority claimed from US09/169,079 external-priority patent/US6824777B1/en

1999-10-08 Application filed by Vegenics Pty Ltd filed Critical Vegenics Pty Ltd

2011-01-05 Application granted granted Critical

2011-01-05 Publication of DE69942981D1 publication Critical patent/DE69942981D1/de

2019-10-09 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Mycology (AREA)
Pathology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)

DE69942981T 1998-10-09 1999-10-08 Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie Expired - Lifetime DE69942981D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/169,079 US6824777B1 (en)	1992-10-09	1998-10-09	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
PCT/US1999/023525 WO2000021560A1 (en)	1998-10-09	1999-10-08	Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY

Publications (1)

Publication Number	Publication Date
DE69942981D1 true DE69942981D1 (de)	2011-01-05

Family

ID=22614189

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69942981T Expired - Lifetime DE69942981D1 (de)	1998-10-09	1999-10-08	Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie

Country Status (13)

Country	Link
US (4)	US8444957B2 (de)
EP (1)	EP1119371B1 (de)
JP (5)	JP4841724B2 (de)
CN (1)	CN100340291C (de)
AT (1)	ATE489108T1 (de)
AU (2)	AU774266B2 (de)
CA (1)	CA2345276C (de)
DE (1)	DE69942981D1 (de)
DK (1)	DK1119371T3 (de)
ES (1)	ES2357406T3 (de)
NO (1)	NO20011759L (de)
NZ (2)	NZ511408A (de)
WO (1)	WO2000021560A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6818220B1 (en)	1994-11-14	2004-11-16	Licentia Ltd.	Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en)	1995-08-01	2008-09-09	Vegenics Limited	Antibodies to VEGF-C
US6361946B1 (en)	1997-02-05	2002-03-26	Licentia Ltd	Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de)	1995-09-08	2003-06-15	Genentech Inc	Vegf-verwandtes protein
US7125714B2 (en)	1997-02-05	2006-10-24	Licentia Ltd.	Progenitor cell materials and methods
EP1119371B1 (de) *	1998-10-09	2010-11-24	Vegenics Limited	Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (de) *	1999-04-13	2005-07-13	Medarex, Inc.	Methoden zur Diagnose und Behandlung metastasierender Prostata-Tumore
WO2001062942A2 (en)	2000-02-25	2001-08-30	Ludwig Institute For Cancer Research	MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
NZ518077A (en)	2000-08-04	2003-11-28	Human Genome Sciences Inc	Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
US7611711B2 (en)	2001-01-17	2009-11-03	Vegenics Limited	VEGFR-3 inhibitor materials and methods
CN1494552A (zh)	2001-01-19	2004-05-05	·��ά��֢�о�Ժ	Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
EP1385864B1 (de)	2001-04-13	2010-06-09	Human Genome Sciences, Inc.	Anti-VEGF-2 Antikörper
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7109165B2 (en)	2001-05-18	2006-09-19	Sirna Therapeutics, Inc.	Conjugates and compositions for cellular delivery
US20040242851A1 (en) *	2001-06-26	2004-12-02	Zhenping Zhu	Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) *	2001-10-01	2003-06-19	Kari Alitalo	Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) *	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of map kinase genes
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8003613B2 (en)	2003-11-17	2011-08-23	University Of Florida Research Foundation, Inc.	Methods and compositions for inducing apoptosis
ATE452188T1 (de)	2004-02-10	2010-01-15	Sirna Therapeutics Inc	Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005087177A2 (en)	2004-03-05	2005-09-22	Ludwig Institute For Cancer Research	Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
DE602006020881D1 (de)	2005-08-15	2011-05-05	Vegenics Pty Ltd	Enen eigenschaften
US9201063B2 (en)	2006-11-16	2015-12-01	General Electric Company	Sequential analysis of biological samples
US8305579B2 (en)	2006-11-16	2012-11-06	Thomas Pirrie Treynor	Sequential analysis of biological samples
US7629125B2 (en)	2006-11-16	2009-12-08	General Electric Company	Sequential analysis of biological samples
US9677125B2 (en)	2009-10-21	2017-06-13	General Electric Company	Detection of plurality of targets in biological samples
EP2538965B1 (de)	2010-02-25	2017-04-12	Schepens Eye Research Institute	Therapeutische zusammensetzungen zur behandlung des syndroms des trockenen auges
DK2632472T3 (en)	2010-10-29	2018-03-19	Sirna Therapeutics Inc	RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2911681A1 (de)	2012-10-26	2015-09-02	Institut National de la Santé et de la Recherche Médicale (INSERM)	Lyve-1-antagonisten zur vorbeugung oder behandlung eines pathologischen leidens in zusammenhang mit lymphangiogenese
ES2771478T3 (es)	2013-02-18	2020-07-06	Vegenics Pty Ltd	Moléculas de unión a ligando y usos de las mismas
EP2994758B1 (de)	2013-05-08	2017-12-20	Opthea Limited	Biomarker für altersbedingte makuladegeneration (amd)
KR102131370B1 (ko)	2013-10-18	2020-07-08	삼성전자주식회사	Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) *	2022-03-01	2022-06-17	中国科学院动物研究所	一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4652639A (en)	1982-05-06	1987-03-24	Amgen	Manufacture and expression of structural genes
US4543439A (en)	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
DE3587657D1 (de)	1984-01-30	1993-12-23	Imp Cancer Res Tech	Verbesserungen an wachstumsfaktoren.
BE1001051A4 (fr)	1987-03-11	1989-06-20	Erba Carlo Spa	Conjugue d'immunoglobuline contenant de l'idarubicine, medicament le contenant et procede de depletion in vitro d'un sous-groupe de lymphocytes t d'une population cellulaire utilisant ce conjugue.
ATE140963T1 (de)	1988-01-22	1996-08-15	Zymogenetics Inc	Verfahren zur herstellung von sekretierten rezeptoranalogen
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5198359A (en)	1989-03-07	1993-03-30	Boehringer Ingelheim International Gmbh	Recombinant protein receptor for il-2
ATE109510T1 (de)	1989-05-22	1994-08-15	Zymogenetics Inc	Pdgf-alpha-rezeptor.
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1992013867A1 (en)	1991-01-31	1992-08-20	Cor Therapeutics, Inc.	Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5256766A (en)	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
EP0536350B1 (de)	1991-02-22	2002-08-07	American Cyanamid Company	Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
US5231001A (en)	1991-03-14	1993-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5367057A (en)	1991-04-02	1994-11-22	The Trustees Of Princeton University	Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en)	1991-04-02	1993-12-14	The Trustees Of Princeton University	Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en)	1991-04-02	1993-02-09	The Trustees Of Princeton University	Nucleic acids encoding hencatoporetic stem cell receptor flk-2
CA2078539C (en)	1991-09-18	2005-08-02	Kenya Shitara	Process for producing humanized chimera antibody
FI943275L (fi)	1992-01-09	1994-07-11	Helsinki University Holding Lt	TIE, uusi endoteelisolun reseptorityrosiinikinaasi
US6331302B1 (en)	1992-01-22	2001-12-18	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
CA2128722A1 (en)	1992-01-22	1993-08-05	William I. Wood	Novel protein tyrosine kinases
US5635177A (en)	1992-01-22	1997-06-03	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
US5660827A (en)	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
US5776755A (en)	1992-10-09	1998-07-07	Helsinki University Licensing, Ltd.	FLT4, a receptor tyrosine kinase
US6824777B1 (en)	1992-10-09	2004-11-30	Licentia Ltd.	Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ES2309119T3 (es)	1992-10-28	2008-12-16	Genentech, Inc.	Utilizacion de antagonistas del factor de crecimiento celular vegf.
US5712395A (en)	1992-11-13	1998-01-27	Yissum Research Development Corp.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en)	1992-11-13	1998-06-09	Sugen, Inc.	Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de)	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
JPH09510093A (ja)	1994-03-08	1997-10-14	ヒューマンジノームサイエンシーズ，インコーポレイテッド	血管内皮細胞増殖因子２
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
GB9410534D0 (en)	1994-05-26	1994-07-13	Lynxvale Ltd	Improvements in or relating to growth factor inhibitors
FI964862A7 (fi) *	1994-06-09	1997-02-10	Orion Yhtymae Oyj	FLT4-reseptorityrosiinikinaasi ja sen käyttö diagnostiikassa ja terapiassa
US5763733A (en)	1994-10-13	1998-06-09	Enzon, Inc.	Antigen-binding fusion proteins
US6645933B1 (en) *	1995-08-01	2003-11-11	Helsinki University Licensing Ltd. Oy	Receptor ligand VEGF-C
WO1998033917A1 (en)	1994-11-14	1998-08-06	The Ludwig Institute For Cancer Research	Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de)	1995-09-08	2003-06-15	Genentech Inc	Vegf-verwandtes protein
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998005293A2 (en) *	1996-08-02	1998-02-12	The Children's Medical Center Corporation	Method of regulating the female reproductive system through angiogenesis inhibitors
ES2251740T3 (es)	1996-08-23	2006-05-01	Ludwig Institute For Cancer Research	Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d).
US7947472B2 (en)	1997-12-24	2011-05-24	Vegenics Limited	Expression vectors and cell lines expressing vascular endothelial growth factor D
EP1119371B1 (de) *	1998-10-09	2010-11-24	Vegenics Limited	Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
KR101681886B1 (ko)	2015-04-06	2016-12-12	서울대학교산학협력단	지르코니아 결합능을 가지는 펩타이드

1999
- 1999-10-08 EP EP99956525A patent/EP1119371B1/de not_active Expired - Lifetime
- 1999-10-08 CA CA2345276A patent/CA2345276C/en not_active Expired - Fee Related
- 1999-10-08 WO PCT/US1999/023525 patent/WO2000021560A1/en not_active Ceased
- 1999-10-08 ES ES99956525T patent/ES2357406T3/es not_active Expired - Lifetime
- 1999-10-08 AU AU13121/00A patent/AU774266B2/en not_active Ceased
- 1999-10-08 NZ NZ511408A patent/NZ511408A/en unknown
- 1999-10-08 NZ NZ529063A patent/NZ529063A/en unknown
- 1999-10-08 JP JP2000575533A patent/JP4841724B2/ja not_active Expired - Fee Related
- 1999-10-08 AT AT99956525T patent/ATE489108T1/de active
- 1999-10-08 DE DE69942981T patent/DE69942981D1/de not_active Expired - Lifetime
- 1999-10-08 DK DK99956525.2T patent/DK1119371T3/da active
- 1999-10-08 CN CNB998142859A patent/CN100340291C/zh not_active Expired - Fee Related
2001
- 2001-04-06 NO NO20011759A patent/NO20011759L/no unknown
2004
- 2004-09-03 AU AU2004208675A patent/AU2004208675B2/en not_active Ceased
2010
- 2010-02-17 US US12/707,423 patent/US8444957B2/en not_active Expired - Fee Related
2011
- 2011-01-04 JP JP2011000273A patent/JP5784310B2/ja not_active Expired - Lifetime
- 2011-08-17 JP JP2011178553A patent/JP5642637B2/ja not_active Expired - Fee Related
2013
- 2013-04-18 US US13/865,711 patent/US20140072511A1/en not_active Abandoned
- 2013-05-07 JP JP2013097900A patent/JP2013209382A/ja active Pending
2014
- 2014-10-01 US US14/504,028 patent/US20150158928A1/en not_active Abandoned
2015
- 2015-04-06 JP JP2015077656A patent/JP2015157829A/ja active Pending
- 2015-12-29 US US14/982,422 patent/US20160184405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2002527404A (ja)	2002-08-27
CN100340291C (zh)	2007-10-03
CN1329504A (zh)	2002-01-02
AU774266B2 (en)	2004-06-24
US20100278736A1 (en)	2010-11-04
AU2004208675A1 (en)	2004-09-30
NZ511408A (en)	2004-04-30
JP2015157829A (ja)	2015-09-03
US20160184405A1 (en)	2016-06-30
AU2004208675B2 (en)	2006-03-02
WO2000021560A9 (en)	2000-09-21
EP1119371A1 (de)	2001-08-01
NZ529063A (en)	2005-07-29
CA2345276C (en)	2011-03-29
EP1119371B1 (de)	2010-11-24
NO20011759D0 (no)	2001-04-06
NO20011759L (no)	2001-06-11
DK1119371T3 (da)	2011-03-07
US20140072511A1 (en)	2014-03-13
AU1312100A (en)	2000-05-01
US8444957B2 (en)	2013-05-21
JP5642637B2 (ja)	2014-12-17
ES2357406T3 (es)	2011-04-26
CA2345276A1 (en)	2000-04-20
JP2012019790A (ja)	2012-02-02
JP2011121957A (ja)	2011-06-23
JP2013209382A (ja)	2013-10-10
ATE489108T1 (de)	2010-12-15
JP4841724B2 (ja)	2011-12-21
WO2000021560A1 (en)	2000-04-20
JP5784310B2 (ja)	2015-09-24
US20150158928A1 (en)	2015-06-11

Publication	Publication Date	Title
DE69942981D1 (de)	2011-01-05	Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
ATE359300T1 (de)	2007-05-15	Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
UA89017C2 (uk)	2009-12-25	ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE272114T1 (de)	2004-08-15	Rezeptoren für il-18
PT842273E (pt)	2005-07-29	Ligando de receptor vegf-c
EP1363920A4 (de)	2004-04-21	Modifizierte psma-liganden und deren verwendung
WO2002057303A3 (en)	2003-12-24	Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
NO20090955L (no)	2001-01-11	BASB029-polynukleotid(er) og -polypeptider fra Neisseria meningitidis
CY1107339T1 (el)	2012-12-19	Mu-1, μελος της οικογενειας υποδοχεα κυτοκινης
IT1307309B1 (it)	2001-10-30	Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
GB9811260D0 (en)	1998-07-22	Novel compounds
GB9820003D0 (en)	1998-11-04	Novel compounds
TR200102745T2 (tr)	2002-05-21	Yeni bileşikler
DE69927017D1 (de)	2005-10-06	Verbindungen aus moraxella catarrhalis
ATE481486T1 (de)	2010-10-15	Gbs toxin rezeptor
DE60039108D1 (de)	2008-07-17	Neue verbindungen aus moraxella catarrhalis
GB0025170D0 (en)	2000-11-29	Novel compounds
GB9918302D0 (en)	1999-10-06	Novel compounds
EP0881286A3 (de)	2000-03-15	Histidine Kinase
AU6832300A (en)	2001-02-19	Novel compounds
BR1100558A (pt)	2008-05-06	famìlia de anticorpos modificados, com elevada afinidade, para tratamento de cáncer.
GB0025169D0 (en)	2000-11-29	Novel compounds
DK1196586T3 (da)	2006-03-27	BASB111-polypeptid og -polynukleotid fra moraxella catharralis
GB9918281D0 (en)	1999-10-06	Novel compounds
ATE274582T1 (de)	2004-09-15	Basb028 polypeptiden und dafür kodierende polynukleotiden aus moraxella catarrhalis